Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions

Abstract

Focal therapy (FT) has emerged as a promising treatment option for localized prostate cancer (PCa), offering oncologic control with reduced adverse effects compared to radical therapies. Various energy modalities, such as high-intensity focused ultrasound, cryotherapy, irreversible electroporation, and focal laser ablation, among others, selectively target malignant prostate tissue while sparing surrounding structures. Advances in imaging techniques, particularly multiparametric magnetic resonance imaging and prostate-specific membrane antigen-positron emission tomography/computed tomography, have improved lesion localization, patient selection, and treatment monitoring. The incorporation of artificial intelligence is enhancing tumor detection and predicting treatment outcomes. Although significant advancements have been made, challenges such as the lack of long-term data, treatment protocol standardization, and regulatory hurdles still limit widespread adoption. This review explores the current state of focal therapy for prostate cancer, highlighting its mechanisms, technological innovations, clinical outcomes, and future directions.